Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

RVV

Revive Therapeutics (RVV)

Revive Therapeutics Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:CSE:RVV
DateTimeSourceHeadlineSymbolCompany
04/18/202210:26AMInvestorsHub NewsWireRevive Therapeutics Announces Publication of Research Data with Bucillamine in COVID-19CSE:RVVRevive Therapeutics Ltd
04/12/20228:00AMInvestorsHub NewsWireRevive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19CSE:RVVRevive Therapeutics Ltd
03/29/20229:57AMInvestorsHub NewsWireRevive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19CSE:RVVRevive Therapeutics Ltd
02/14/20226:53AMInvestorsHub NewsWireRevive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19CSE:RVVRevive Therapeutics Ltd
01/17/20229:13AMInvestorsHub NewsWireRevive Therapeutics Provides Update of Psilocybin Pharmaceutical ProgramsCSE:RVVRevive Therapeutics Ltd
01/07/20228:05AMInvestorsHub NewsWireRevive Therapeutics Clarifies Status of Its Phase 3 Clinical Trial for Bucillamine in COVID-19CSE:RVVRevive Therapeutics Ltd
08/18/20216:00AMInvestorsHub NewsWireRevive Therapeutics Signs Exclusive Worldwide License Agreement For Medicinal Mushroom Ganoderma Lucidum To Treat CancerCSE:RVVRevive Therapeutics Ltd
08/12/20219:56AMInvestorsHub NewsWireRevive Confirms No Material Undisclosed InformationCSE:RVVRevive Therapeutics Ltd
08/10/20218:52AMInvestorsHub NewsWireRevive Therapeutics Provides Update on Psychedelics Clinical Product PipelineCSE:RVVRevive Therapeutics Ltd
06/28/20218:00AMInvestorsHub NewsWireRevive Therapeutics Approved to Trade on the OTCQB MarketCSE:RVVRevive Therapeutics Ltd
06/08/20219:12AMInvestorsHub NewsWireRevive Therapeutics Partners with Supriya to Pursue EUA for Bucillamine to Treat COVID in IndiaCSE:RVVRevive Therapeutics Ltd
05/17/20219:48AMInvestorsHub NewsWireRevive Therapeutics Enters into Feasibility Agreement with LTS Lohmann to Develop Oral Psilocybin Thin Film StripCSE:RVVRevive Therapeutics Ltd
05/03/20219:32AMInvestorsHub NewsWireRevive Therapeutics Enters Into Research Agreement with UCSF For Bucillamine As Potential Treatment For Severe COVID-19CSE:RVVRevive Therapeutics Ltd
04/22/20218:26AMInvestorsHub NewsWireRevive Therapeutics Announces Successful Research Results for Oral Thin Film Psilocybin and Filing of U.S. Provisional ....contCSE:RVVRevive Therapeutics Ltd
03/24/20219:15AMInvestorsHub NewsWireRevive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19CSE:RVVRevive Therapeutics Ltd
02/11/20218:05AMInvestorsHub NewsWireRevive Therapeutics Provides Update on Cannabinoid Pharmaceuticals ProgramCSE:RVVRevive Therapeutics Ltd
01/27/20218:13AMInvestorsHub NewsWireRevive Therapeutics in Phase 3 clinical trial for COVID-19 treatmentCSE:RVVRevive Therapeutics Ltd
01/18/20219:51AMInvestorsHub NewsWireHow Combat Sports Are Researching Micro-Dosing Psychedelics To Treat Brain InjuriesCSE:RVVRevive Therapeutics Ltd
12/31/20208:30AMInvestorsHub NewsWireDr. John Fahy Joins Revive Therapeutics as Scientific and Clinical Advisor for COVID-19 FDA Phase 3 StudyCSE:RVVRevive Therapeutics Ltd
12/22/202011:05AMInvestorsHub NewsWireRevive Therapeutics Announces LOI to Acquire PharmaTher's Psilocybin ProgramCSE:RVVRevive Therapeutics Ltd
10/30/20201:39PMInvestorsHub NewsWireRevive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19CSE:RVVRevive Therapeutics Ltd
07/31/20209:46AMInvestorsHub NewsWireRevive Therapeutics Announces U.S. FDA Approval of Confirmatory Phase 3 Clinical Trial for Bucillamine in COVID-19CSE:RVVRevive Therapeutics Ltd
04/23/20209:47AMInvestorsHub NewsWireRevive Therapeutics Announces U.S. FDA Recommendation to Proceed Directly Into A Phase 3 Confirmatory Clinical TrialCSE:RVVRevive Therapeutics Ltd
 Showing the most relevant articles for your search:CSE:RVV